Indivior (INVVY) Stock Price, News & Analysis

Company Overview

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing treatments for substance-use disorders and other conditions affecting the brain. Its portfolio is centered on medications for opioid-use disorder, including SUBLOCADE, a once-monthly extended-release buprenorphine injection, and SUBOXONE, a buprenorphine and naloxone product available in sublingual formulations. The company also markets BRIXADI, an extended-release buprenorphine injection, and OPVEE, a nalmefene nasal spray designed to provide emergency treatment for known or suspected opioid overdose.

Indivior also offers products in related behavioral-health areas, including PERSERIS, a long-acting injectable formulation of risperidone used to treat schizophrenia in adults. The company serves healthcare providers and patients primarily in the United States, while also operating and commercializing products in selected international markets.

Indivior was established in 2014 after being separated from Reckitt Benckiser Group, which had acquired the business through its purchase of the pharmaceutical company formerly known as Reckitt Benckiser Pharmaceuticals. The company is headquartered in Richmond, Virginia, and is led by Chief Executive Officer Mark Crossley.

Key Stats

• Today's Range: $21.64 to $21.85
• 50-Day Range: $21.85 to $21.85
• 52-Week Range: $14.76 to $35.50
• Volume: 8,100 shs
• Average Volume: 3,825 shs
• Market Capitalization: $3.01 billion
• P/E Ratio: 20.81
• Dividend Yield: N/A
• Price Target: $50.00
• Consensus Rating: Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Indivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Indivior has a consensus price target of $50.00, representing about 128.9% upside from its current price of $21.85.

Amount of Analyst Coverage

Indivior has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 46.77%

Earnings Growth

Earnings for Indivior are expected to grow by 46.77% in the coming year, from $1.24 to $1.82 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is 20.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is 20.81, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.02.

Price to Book Value per Share Ratio

Indivior has a P/B Ratio of 15.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for INVVY.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indivior does not currently pay a dividend.

Dividend Growth

Indivior does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Indivior has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.05% of the stock of Indivior is held by institutions.

Company Calendar

• Today: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:INVVY
• Previous Symbol: NASDAQ:INVVY
• CIK: 1625297
• Web: www.indivior.com
• Phone: 804-379-1090
• Fax: 804-379-1215
• Employees: 800
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Indivior: $50.00
• High Price Target: $50.00
• Low Price Target: $50.00
• Potential Upside/Downside: +128.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 20.81
• Forward P/E Ratio: 17.62
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $791 million
• Price / Sales: 3.81
• Cash Flow: $1.15 per share
• Price / Cash Flow: 18.94
• Book Value: $1.45 per share
• Price / Book: 15.07

Miscellaneous

• Outstanding Shares: 137,880,000
• Free Float: N/A
• Market Cap: $3.01 billion
• Optionable: Not Optionable
• Beta: 0.35